To evaluate the late-effects of allogeneic bone marrow transplantation (BMT) on endocrine function 20 adults (10 females, 10 males) with hematological malignancies were studied after a mean of 3.2 years (range 1.0-10.0) following BMT. The mean age of patients at the time of BMT was 39 years. Dynamic tests of the hypothalamicpituitary axis included growth hormone releasing hormone (GHRH), gonadotropin releasing hormone (GnRH) and thyrotropin releasing hormone (TRH) stimulations with measurements of serum growth hormone (GH), follicle stimulating hormone (FSH), luteinizing hormone (LH), thyrotropin (TSH) and prolactin (PRL) responses. Adrenal function was assessed with the adrenocorticotropin (ACTH) test. Five patients (25%) had a subnormal GH response to GHRH stimulation, but all had a normal serum insulin-like growth factor I (IGF-I) value. There was an inverse nonlinear relationship between the body mass index (BMI; kg/m 2 ) and GH response but no relation between the GH response and total body irradiation (TBI), intrathecal treatment or occurrence of graft-versus-host disease. In females, serum FSH and LH basal levels and responses to GnRH, in spite of oestrogen substitution therapy in 9/10 patients, indicated ovarian failure and early menopause. Most responses to GnRH were delayed. All males had elevated serum basal FSH levels indicating damage in seminiferous tubulus and infertility. Serum basal LH was elevated only in four males but testosterone values were all within normal limits. However, the mean free androgen index (FAI) was in the low normal range, and two subjects had abnormally low FAI. Serum free thyroxine (fT4) levels were normal in all but one, but an exaggerated TSH response to TRH occurred in seven patients (35%). Four of them had received TBI and one total nodal irradiation suggesting radiation-induced damage to the thyroid gland. In 19 of the 20 patients, adrenal function judged with ACTH test was normal. We conclude that functional impairments of the hypothalamus-pituitary-gonad/thyroid axis are common while disturbances in GH, adrenal and prolactin occur less often in patients after intensive treatment and BMT. Typically, the target organ is more commonly affected Allogeneic bone marrow transplantation (BMT) is currently the treatment of choice for many hematological diseases and the number of cured patients is increasing. In connection with BMT, patients are exposed to potent cytotoxic chemotherapy and often to irradiation. Pretransplant preparative regimens most typically include high-dose cyclophosphamide (CY) in conjunction either with busulphan (BU) or total body irradiation (TBI).
than the hypothalamus-pituitary axis. In spite of normal serum testosterone and LH values, serum FAI may reveal androgen deficiency. Keywords: BMT; pituitary hormones; FSH; LH; TSH; cortisol Allogeneic bone marrow transplantation (BMT) is currently the treatment of choice for many hematological diseases and the number of cured patients is increasing. In connection with BMT, patients are exposed to potent cytotoxic chemotherapy and often to irradiation. Pretransplant preparative regimens most typically include high-dose cyclophosphamide (CY) in conjunction either with busulphan (BU) or total body irradiation (TBI).
There is a high risk of gonadal 1 and thyroid 2 dysfunction among patients cured by BMT. In children, growth is often adversely affected. 3 The degree of endocrinological disturbances is associated with age, type and quantity of cytotoxic treatment, TBI and the TBI radiation regimen. 4 In this study the late-effects on pituitary, gonad, thyroid and adrenal function were assessed in adults who had undergone BMT.
Patients and methods

Patients
Twenty patients were studied, with a mean age of 39 years (range at the time of BMT. The mean interval from BMT to examination was 3.2 years (range 1.0-10.0) ( Table 1) . Diagnoses included acute myelogenous leukemia (n = 5), chronic myelogenous leukemia (n = 5), multiple myeloma (n = 3), lymphoblastic lymphoma (n = 2), severe aplastic anemia (n = 2), acute lymphatic leukemia (n = 1), non-Hodgkin's lymphoma (intermediate grade; n = 1) and Burkitt's lymphoma (n = 1). Conditioning regimens are presented in Table 2 . Patients received the allogeneic bone marrow transplant from an HLA-identical and MLC-negative sibling (n = 19) or from a matched unrelated donor (n = 1). Graft-versus-host disease (GVHD) prophylaxis consisted of methotrexate (total of 45 mg/m 2 ) and cyclosporine.
The study was approved by the joint ethics committee of the Turku University and the Turku University Central Hospital. Informed consent was obtained from all patients. Graft-versus-host disease (GVHD) at the time of assessment. Mild: dry skin or skin rash. Extensive: skin rash and gut involvement or liver involvement (or both). Roche, Basle, Switzerland) with dosages given in the literature. 5, 6 The adrenal axis was assessed with the adrenocorticotropin (ACTH) test (Cortrophin, 250 g i.m.; Organon, Oss, The Netherlands).
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Tests were performed in the morning (starting time 7.30 am) after the patients had had overnight rest and fast. During the tests the patients laid supine and blood samples were drawn through an intravenous cannula inserted in a forearm vein. The cannula and three-way stopcock were inserted and heparinized 20 min before sampling. The heparinized blood was discarded and only unheparinized blood was accepted for the analyses. Blood samples for GH, FSH, LH, TSH and PRL were taken at −20, 0, +20, +40, +60 and +80 min relative to i.v. injection of the releasing hormones. The ACTH test was performed immediately after the releasing tests. Cortisol concentrations were measured at 0, +30 and +60 min. Samples for the determination of basal serum concentrations of insulin-like growth factor I (IGF-I), estradiol, testosterone, sex hormone binding globulin (SHBG), free thyroxine (fT4), thyroid antimicrosome antibodies (McAb) were drawn and also samples for testing of osmolality of serum and urine. The free androgen index (FAI; 1000 × testosterone/SHBG) was calculated. Body mass index (BMI) was calculated as weight (kg) divided by height (m) squared.
Analytical methods
Serum FSH and LH levels were measured by time-resolved immunofluorometric assays (TR-IFMA; Delfia, Wallac, Turku, Finland). Commercial immunoradiometric assays were used for measurement of serum GH (CIS, Gif-SurYvette, France) and TSH and PRL (Spectria, Orion Diagnostica, Helsinki, Finland). SHBG was determined with a ligand binding assay 7 in which the binding of radiolabelled dihydrotestosterone (Amersham, Bucks, UK) to SHBG in serum was measured using ammonium sulphate precipitation. Serum testosterone was determined after hexane/ether extraction by radioimmunoassay (RIA) as described by Castro et al 8 using (1,2,6,7-3 H) testosterone (Amersham) as tracer and testosterone 3-CMO-BSA antiserum (Orion Diagnostica). Commercial radioimmunoassays were used for measurement of serum IGF-I (somatomedin C; Somatomedin C 125 I RIA kit; Incstar Corporation, Stillwater, MN, USA), estradiol and cortisol (Spectria; Orion Diagnostica), and free T4 (Amerlex-M free T4 RIA kit; Amersham).
Reference intervals for the hormones studied are shown in Table 3 .
Statistics
Analysis of covariance was used for evaluating the effects of BMI, TBI, intrathecal treatment and GVHD on the GH responses to GHRH.
Results
GH and IGF-I
Five patients had a low response (maximum Ͻ5 g/l) in the GHRH test. An inverse nonlinear relationship between the BMI and GH response was observed ( Figure 1 ). No effect of total dose of methotrexate, occurrence of GVHD or TBI was found on the levels of GH response in the GHRH test. Three patients (15%) had an apparent rise in GH values between −20 min and 0 samples, ie before the GHRH injection, which indicates a normal physiologic response to stress. Age of patients at the time of examination varied from 33 to 54 years except for one male patient (age 19). The mean IGF-I, 18 nmol/l, was the same in males and females and all IGF-I values were within normal limits (also in the young male patient; 32 nmol/l).
FSH, LH, gonadal function
Females: All but one female had high basal serum FSH and LH levels as compared to premenopausal reference values: 40 U/l (range 1-120) and 32 U/l (range 7-65), Table 3 Reference intervals for the laboratory measurements. In the releasing tests the maximum response normally occurs at +20 min. The GnRH test is performed during the first 2 weeks of the menstrual cycle when applicable 
Reference interval
Increment from the basal value Ͼ200 nmol/l, and at least Ͼ500 nmol/l at the end of the test Basal serum testosterone (nmol/l) Females 0. respectively (Table 4) . The exception was patient number 10 who had very low basal values and lacked a response to the releasing hormone; she had had a miscarriage because of ovum abortivum 1 week earlier. The FSH response to GnRH i.v. injection was subnormal in all subjects and the peak value was delayed in seven. LH response was subnormal in two and delayed in four. Nine females were receiving menopausal substitution therapy ( Table 1 ). The mean serum estradiol level was 165 pmol/l ranging from Ͻ50-324 pmol/l (Table 4) . One patient had a marginally lowered serum testosterone level and one had an increased FAI, otherwise all females had normal androgen status.
Males: All males had raised serum basal FSH levels with a mean of 18 U/l (range [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . The response of serum FSH to administration of GnRH was abnormally low in all but one patient and delayed in nine, but the curves were flat (Figure 2 ). Serum basal LH was elevated in four males ( Table 4 ). The LH responses to GnRH were normal and the peak value was most often situated normally. Serum testosterone was normal in all males with the mean of 18 nmol/l (range [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . Two of the subjects had abnormally low FAIs (250 and 370), and the mean FAI was within the lower reference range at a mean of 500 (range 250-780; Table 4 ).
Thyroid function
No patient had a history of thyroid dysfunction, and at the time of examination all patients were clinically euthyroid. Serum basal TSH was normal in all but one patient (5.1 mU/l). An exaggerated TSH response to TRH occurred in Table 3 .
seven patients (35%); the TSH response was high in two patients (over 50 mU/l), and moderately high in five (over 30 mU/l). Four of these patients had received TBI and one total nodal irradiation with the conditioning regimen. Timing of the peak value was normal in all patients (+20 min; Figure 2 ). Serum fT4 was normal in all but one patient with a mean of 15.6 pmol/l (range 10.5-22); raised McAbs were not found. One patient with a low normal fT4 (10.5 pmol/l) and a normal basal TSH (4.1 mU/l) had an exaggerated TSH response to the releasing test (maximum TSH 42 mU/l).
PRL
The basal serum PRL value was slightly elevated in two patients (18 and 20 g/l) and one of them also had an abnormally low PRL response to TRH. One was taking no medication and the other used estradiol patches 50 g twice a week. In a third patient the peak occurred at +40 min, but in all other patients (n = 18; 90%) the peak PRL response to TRH occurred normally ( Figure 2 ).
Adrenocortical function
The ACTH test was done after the GHRH-GnRH-TRH releasing tests between 9.30 and 10. 509-1167 nmol/l; mean 864 nmol/l) of serum cortisol to ACTH i.m. injection was normal. Three patients were on prednisone (2.5-15 mg/day) but two still had normal responses to ACTH.
Discussion
Many patients are long-term survivors after BMT, and need continuous medical follow-up including endocrine functions. Multiple endocrine abnormalities may occur especially after TBI-containing regimens, but patients after high-dose cytostatics are also not exempt. Hypopituitarism is a well-known delayed complication of radiotherapy to the hypothalamic-pituitary axis but has been observed only at cumulative total doses of у20 Gy to the brain. 9 The threshold dose can, however, be lower in patients treated at the same time with high doses of methotrexate or intrathecal chemotherapy. The dose of TBI for our patients was 12 Gy and hypopituitarism was not a central finding in our study.
There are many studies dealing with GH secretion in children who have undergone BMT. The GH secretion response to provocative tests is impaired 10 but spontaneous GH secretion may also be reduced. 11 The reduced growth rate after TBI may be due to multiple factors, but impaired GH secretion is often the most important factor. GH generates growth mainly by enhancing production of growth factors such as IGF-I. Inadvertent irradiation of the liver and other tissues during TBI through secondary radiation contributes to defective production of IGF-I. In children it has, however, been shown that after cranial irradiation insulinlike growth factor binding protein (IGFBP-3) is not a useful screening test for GH deficiency. 12 In adults GH secretion may be less vulnerable than in children. 13 The impact of GH deficiency on the health of adults is an unresolved issue. To detect GH deficiency, serum basal GH levels are not sufficiently sensitive to be the only test.
14 In estimating the GH reserves of adults, a provocative test must be used. Insulin-induced hypoglycemia may be the best one, 15 but is cumbersome. We used the GHRH test to estimate GH reserves. GH responses seemed to be related to BMI (Figure 1) . This relationship between GH responses and BMI or body weight has been reported previously. 16, 17 However, we were surprised to see this relationship in our patients who were within the normal range of BMI (with two exceptions). The GHRH dose we used may mask diminished GH reserves; however, five blunted responses were observed possibly indicating impairment at the hypothalamic-pituitary level. Previously diminished GH responses to GHRH after a single-dose of TBI 18 and normal GH responses to insulin-induced hypoglyceamia after fractionated TBI 13 have been reported in adults. Our finding of diminished GH responses after fractionated TBI indicates that other factors in radiation schedules aside from the number of fractions may have an effect on GH reserves. Four of the five subnormal GH responses occurred in subjects with normal BMIs indicating that other factors apparently have an effect on the GH response besides BMI. IGF-I might be a better marker of pituitary GH production in adults because IGF-I reflects 'cumulatively' the spontaneous GH secretion. 19 This agrees well with our findings of normal serum IGF-I in our patients. Even if serum IGF-I declines with age, the impact of this has no meaningful effect on our results due to the narrow age range of our patients. However, it has been shown that in GH deficiency there is an overlap in IGF-I values 15 and IGF-I is perhaps a better indicator of pituitary hyperfunction (acromegaly) than hypofunction.
Disturbances of gonadal function are an inevitable consequence of TBI or chemotherapy with agents like cyclophosphamide or busulphan. The dose of irradiation needed to produce permanent sterility in females appears to be related to age, 20 ie the number of remaining oocytes at the time of irradiation, and also to the total dose of radiation and schedule of administration. Gonadal function in males is often more vulnerable than in females 21 after aggressive chemotherapy, and lower doses may cause permanent germinal epithelial damage. The damage causes a constant rise in FSH and infertility in males. 22 Therefore, it may be unnecessary to undertake a semen analysis in cases where the FSH level is elevated. 23 Since all our male patients had a high serum basal FSH indicating germinal cell damage we did not undertake sperm analysis. However, late spontaneous recovery of spermatogenesis occurs in a small percentage of males who have undergone BMT and is more likely in younger patients who have received cytotoxic chemotherapy without TBI. The Leydig cells are more resistant to irradiation than is the germinal epithelium, 24 and in agreement with this, serum testosterone values were normal in all our patients, as were most of the serum LH values. In spite of this, serum FAI was low normal or abnormally low (two subjects). Thus, testosterone replacement therapy may be needed for male patients to prevent consequences of hypoandrogenism. In contrast to males, all females have primary ovarian failure after BMT and they need estrogen replacement therapy because of early menopause. Hormone replacement therapy is the best way to prevent complications of early menopause such as osteoporosis and accelerated atherosclerosis. Our patients used estradiol alone for replacement therapy, if they had undergone hysterectomy, and otherwise an estradiol progesterone combination. Our females had no clinical symptoms of menopause, but in spite of the substitution therapy, many had very low estradiol levels together with high FSH and LH levels. This implies that the substitution dose of estradiol was too low for the hypothalamus-pituitary axis. In many patients the FSH response in the releasing test was delayed which may indicate a defect at the hypothalamic level.
In contrast to radiotherapy, it is usually thought that chemotherapy before BMT does not contribute to the development of thyroid dysfunction. However, if the conditioning regimen contains TBI, 12-56% of children will have thyroid abnormalities. 25 Thyroid dysfunction is more common after single-dose TBI than after fractioned TBI. 26 The most common biochemical finding is a mildly elevated basal serum TSH and normal serum fT4 27 indicating radiation-induced damage to the thyroid. This occurs both in children and adults and the damage may be permanent. We found only one patient with mild subclinical hypothyroidism. However, the TSH response to TRH was exaggerated in seven (35%) patients but only four had received TBI and one had had total nodal irradiation. These patients may, perhaps, be predisposed to hypothyroidism in the future and will need to be followed carefully. In children, subclinical hypothyroidism usually requires replacement therapy. This may even reduce the risk of thyroid malignancy. Subclinical thyroid dysfunction is common but the pattern of biochemical thyroid abnormalities may be complex.
Two of our 20 patients had slightly elevated prolactin levels after TBI. A similar observation has been reported previously. 9 Hyperprolactinemia is quite common in patients treated with radiation schedules at higher doses in other diseases and it is considered a marker of hypothalamic damage. [28] [29] [30] [31] Hyperprolactinemia may be due to partial loss of inhibitory control of prolactin secretion following impaired dopamine secretion. One of our TBI patients had a slightly elevated basal value of prolactin (20 g/l) and a high response to the releasing test (maximum PRL 96 g/l). Basal serum PRL levels may be elevated and the TRH-stimulated PRL release may be exaggerated in hypothyroidism, 32 which was not the case in this patient (TSH 1.6 mU/l and fT4 15 pmol/l).
The adrenal gland is quite radioresistant. Crowne et al 33 observed no disruption of spontaneous ACTH or cortisol secretion in children after a low dose (18-24 Gy) of cranial irradiation. 33 If the patient receives long-term glucocorticoid therapy for GVHD, function of the adrenals may be downregulated. A normal or borderline morning serum cortisol value does not necessarily predict response to a stress situation. Hypothalamic-pituitary function returns before adrenocortical function as the hypothalamic-pituitary-adrenal axis recovers from suppression, 34 and a normal cortisol response to ACTH in this setting suggests that the hypothalamic-pituitary function is also normal. In our patients response to ACTH was normal, even in two of the three patients who were receiving prednisone therapy. The only abnormal test was probably due to the suppressive effect of oral prednisone (dose 15 mg/day). It is possible, however, that the ACTH dose of 250 g may not reveal mild adrenal hypofunction. 35 In summary, the hypothalamus-pituitary axis seems to remain intact and most hormonal disturbances appear at the target organ level. Impairment of gonadal function is the most common endocrine sequel after BMT. Females have early menopause after BMT and it is important to introduce estrogen replacement therapy in a timely manner to control serum estradiol levels. Males typically have increased FSH levels indicating infertility. FAI may reveal androgen deficiency, while serum LH and testosterone are normal, and is a valuable parameter in the endocrinological followup of post-BMT patients.
